Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spector R. A revolution in the treatment of obesity. Am J Med. 2024;S0002–9343(24):00334–6.

Google Scholar 

Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336–47.

Article  CAS  PubMed  Google Scholar 

Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534.

Article  CAS  PubMed  Google Scholar 

Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94–105.

Article  CAS  PubMed  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.

Article  CAS  PubMed  Google Scholar 

Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrøm SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437):1635–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roland N, Neumann A, Hoisnard L, Duranteau L, Froelich S, Zureik M, et al. Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ. 2024;27: e078078.

Article  Google Scholar 

Swital M, Drouin J, Miranda S, Bakchine S, Botton J, Dray-Spira R. Use of multiple sclerosis disease-modifying therapies during pregnancy in France: nationwide study between 2010 and 2021. Mult Scler. 2024;30(2):227–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tuppin P, Rudant J, Constantinou P, Gastaldi-Ménager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl. 4):S149–67.

Article  PubMed  Google Scholar 

Rachas A, Gastaldi-Ménager C, Denis P, Barthélémy P, Constantinou P, Drouin J, et al. The economic burden of disease in France from the national health insurance perspective: the healthcare expenditures and conditions mapping used to prepare the French Social Security Funding Act and the Public Health Act. Med Care. 2022;60(9):655–64.

Article  PubMed  PubMed Central  Google Scholar 

Liao TF, Bolano D, Brzinsky-Fay C, Cornwell B, Fasang AE, Helske S, et al. Sequence analysis: its past, present, and future. Soc Sci Res. 2022;107: 102772.

Article  PubMed  Google Scholar 

Studer M, Ritschard G. What matters in differences between life trajectories: a comparative review of sequence dissimilarity measures. J Royal Stat Soc A. 2016;179(2):481–511.

Article  Google Scholar 

Martin GL, Atramont A, Mazars M, Tajahmady A, Agamaliyev E, Singer M, et al. Days spent at home and mortality after critical illness: a cluster analysis using nationwide data. Chest. 2023;163(4):826–42.

Article  PubMed  Google Scholar 

Gabadinho A, Ritschard G, Müller NS, Studer M. Analyzing and visualizing state sequences in R with TraMineR. J Stat Soft. 2011;40(4):147.

Article  Google Scholar 

Fontbonne A, Currie A, Tounian P, Picot MC, Foulatier O, Nedelcu M, et al. Prevalence of overweight and obesity in France: the 2020 Obepi-Roche Study by the “Ligue Contre l’Obésité.” J Clin Med. 2023;12(3):925.

Article  PubMed  PubMed Central  Google Scholar 

Czernichow S, Paita M, Nocca D, Msika S, Basdevant A, Millat B, et al. Current challenges in providing bariatric surgery in France: a nationwide study. Medicine (Baltimore). 2016;95(49): e5314.

Article  PubMed  Google Scholar 

Chevreul K, Berg Brigham K, Durand-Zaleski I, Hernandez-Quevedo C. France: health system review. Health Syst Transit. 2015;17(3):1–218 (xvii).

PubMed  Google Scholar 

Muscogiuri G, Verde L, Vetrani C, Barrea L, Savastano S, Colao A. Obesity: a gender-view. J Endocrinol Invest. 2024;47(2):299–306.

Article  CAS  PubMed  Google Scholar 

Lazzati A. Epidemiology of the surgical management of obesity. J Visc Surg. 2023;160(2S):S3-6.

Article  CAS  PubMed  Google Scholar 

Kochkodan J, Telem DA, Ghaferi AA. Physiologic and psychological gender differences in bariatric surgery. Surg Endosc. 2018;32(3):1382–8.

Article  PubMed  Google Scholar 

Lazzati A, Guy-Lachuer R, Delaunay V, Szwarcensztein K, Azoulay D. Bariatric surgery trends in France: 2005–2011. Surg Obes Relat Dis. 2014;10(2):328–34.

Article  PubMed  Google Scholar 

Cantor AG, Nelson HD, Pappas M, Atchison C. Preventing obesity in midlife women: a systematic review for the Women’s Preventive Services Initiative. Ann Intern Med. 2022;175(9):1275–84.

Article  PubMed  Google Scholar 

Wharton S, Davies M, Dicker D, Lingvay I, Mosenzon O, Rubino DM, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14–9.

Article  CAS  PubMed  Google Scholar 

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.

Article  CAS  PubMed  Google Scholar 

Szczerbinski L, Florez JC. Precision medicine of obesity as an integral part of type 2 diabetes management: past, present, and future. Lancet Diabetes Endocrinol. 2023;11(11):861–78.

Article  PubMed  Google Scholar 

Chen S, Dai Y, Ma X, Peng H, Wang D, Wang Y. Personalized optimal nutrition lifestyle for self obesity management using metaalgorithms. Sci Rep. 2022;12(1):12387.

Article  CAS  PubMed  PubMed Central  Google Scholar